Cargando…

Clinical significance of soluble programmed cell death‐ligand 1 in hepatitis B virus‐related hepatocellular carcinoma

Detalles Bibliográficos
Autores principales:	Yang, Zhongxia, Liu, Xiaojun, Zhou, Ping, Mao, Yongwu, Li, Junfeng, Mao, Xiaorong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154365/ https://www.ncbi.nlm.nih.gov/pubmed/37153113 http://dx.doi.org/10.1002/mco2.225

Ejemplares similares

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
por: Banerjee, Debasree, et al.
Publicado: (2018)

Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
por: Liu, Xiaojun, et al.
Publicado: (2016)

Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C
por: Yamagiwa, Satoshi, et al.
Publicado: (2017)

Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
por: Tominaga, Tetsuro, et al.
Publicado: (2019)

Survey of Hepatitis B Virus Co‐infection in Hepatitis C Virus‐infected Patients Suffering from Chronic Hepatitis and Hepatocellular Carcinoma in Japan
por: Koike, Katsuro, et al.
Publicado: (1999)

Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
por: Chen, Kaiyan, et al.
Publicado: (2016)

Hepatocellular carcinoma in patients with B and C virus hepatitis without cirrhosis
por: Carvalho, Kellyane Santana Dias, et al.
Publicado: (2017)

The impact of hepatitis C virus and human immunodeficiency virus coinfection on survival in patients with hepatocellular carcinoma
por: Spartalis, Eleftherios, et al.
Publicado: (2017)

Anti‐programmed death ligand 1 therapy‐induced type 1 diabetes presenting with multiple islet‐related autoantibodies
por: Honoki, Hisae, et al.
Publicado: (2019)

Implementation of programmed death-ligand 1 (PD-L1) expression as a prognostic biomarker for patients with lung cancer
por: Li, Huijuan, et al.
Publicado: (2022)

Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis
por: Wei, Wei, et al.
Publicado: (2018)

The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas
por: Liu, Shujun, et al.
Publicado: (2020)

Increased Expression of Programmed Death Ligand 1 in Hepatocellular Carcinoma of Patients with Hepatitis B Virus Pre-S2 Mutant
por: Teng, Chiao-Fang, et al.
Publicado: (2020)

Effect of Lactate on Epigenetic Regulation in the Development of Hepatitis B Virus-related Hepatocellular Carcinoma
por: Mahmoudvand, Shahab, et al.
Publicado: (2022)

The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma
por: Chang, Boyang, et al.
Publicado: (2018)

Responsibility of hepatitis C virus in the development of hepatocellular carcinoma: From molecular alterations to possible solutions
por: Bertino, Gaetano, et al.
Publicado: (2018)

Is positivity for hepatitis C virus antibody predictive of lower risk of death in COVID-19 patients with cirrhosis?
por: Mangia, Alessandra, et al.
Publicado: (2020)

The predictive role of soluble programmed death ligand 1 in digestive system cancers
por: Ruan, Jian, et al.
Publicado: (2023)

Recognising the clinically significant macrotrabecular massive variant of hepatocellular carcinoma
por: Seow, Dominique Yuan Bin, et al.
Publicado: (2022)

Autophagy related protein 9A increase in hepatitis B virus-associated hepatocellular carcinoma and the role in apoptosis
por: Kimkong, Ingorn, et al.
Publicado: (2020)

Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
por: Yang, Min-Wei, et al.
Publicado: (2019)

Digital Slides as an Effective Tool for Programmed Death Ligand 1 Combined Positive Score Assessment and Training: Lessons Learned from the “Programmed Death Ligand 1 Key Learning Program in Head-and-Neck Squamous Cell Carcinoma”
por: Eccher, Albino, et al.
Publicado: (2021)

Tenofovir over Entecavir on Hepatocellular Carcinoma Prevention: Potential Mechanisms and Suitable Population
por: Huang, Yongfa, et al.
Publicado: (2022)

Targeting RAS guanyl releasing protein 1 promotes T lymphocytes infiltrations and improves anti‐programmed death receptor ligand 1 therapy response of triple‐negative breast cancer
por: Chen, Xi, et al.
Publicado: (2023)

Prognostic and predictive role of soluble programmed death ligand-1 in head and neck cancer
por: Molga-Magusiak, Maria, et al.
Publicado: (2023)

Virus Hepatitis Update
por: Hewitt, P E
Publicado: (2000)

Pelvic Bone Fractures Mimicking Bone Metastases in a Patient with Hepatitis B Virus-Associated Liver Cirrhosis and Hepatocellular Carcinoma
por: Lee, Dong Hyeon, et al.
Publicado: (2012)

The significance of programed cell death‐ligand 1 expression in vestibular schwannoma
por: Lee, Se A, et al.
Publicado: (2023)

Enhancement of Programmed Death Ligand 2 on Hepatitis C Virus Infected Hepatocytes by Calcineurin Inhibitors
por: Koike, Kazuko, et al.
Publicado: (2015)

Shared Human/Rabbit Ligands for Rabbit Hemorrhagic Disease Virus
por: Nyström, Kristina, et al.
Publicado: (2012)

Semen and viruses: significance during the transmission of infections
por: Cardona Maya, Walter D., et al.
Publicado: (2022)

The Change of Soluble Programmed Death Ligand 1 (sPD-L1) in Plasma of Small Cell Lung Cancer and Its Clinical Significance
por: Lu, Feijie, et al.
Publicado: (2022)

Inhibitors of PARP-1 exert inhibitory effects on the biological characteristics of hepatocellular carcinoma cells in vitro
por: Mao, Xiaorong, et al.
Publicado: (2017)

Immune checkpoint molecules soluble program death ligand 1 and galectin‐9 are increased in pregnancy
por: Enninga, Elizabeth Ann L., et al.
Publicado: (2017)

High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma
por: Lu, Tianzhu, et al.
Publicado: (2020)

The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis
por: Huang, Pei, et al.
Publicado: (2021)

Soluble monomeric human programmed cell death-ligand 1 inhibits the functions of activated T cells
por: Liang, Zhaoduan, et al.
Publicado: (2023)

Pityriasis rosea in a patient with retrovirus infection and a history of syphilis and positive results of infection with hepatitis A virus, hepatitis B virus and hepatitis C virus
por: Neneman, Anna, et al.
Publicado: (2017)

Co-infection of hepatitis B virus and hepatitis C virus with human immunodeficiency virus infection: A cross-sectional study
por: Singh, Satyendra Kumar, et al.
Publicado: (2016)

Two distinct stem cell‐like subtypes of hepatocellular carcinoma with clinical significance and their therapeutic potentials
por: Lee, Sung Hwan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_phdr8b93uldjmqqbdhfm2qdc8q